Safety and Efficacy of a Turkey Herpesvirus Vector Laryngotracheitis Vaccine for Chickens

  title={Safety and Efficacy of a Turkey Herpesvirus Vector Laryngotracheitis Vaccine for Chickens},
  author={Motoyuki Esaki and L. Christopher Noland and Tim Eddins and Alecia Godoy and Sakiko Saeki and Shuji Saitoh and Atsushi Yasuda and Kristi Moore Dorsey},
  booktitle={Avian diseases},
SUMMARY Turkey herpesvirus vector laryngotracheitis vaccine (HVT/LT) expressing the glycoprotein B gene of laryngotracheitis virus (LTV) has been developed. In vitro growth kinetics of HVT/LT were similar to those of parental turkey herpesvirus (HVT), FC-126 strain. Genetic and phenotypic stabilities of HVT/LT after in vitro (in cell culture) or in vivo (in chickens) passage were confirmed by various assays, including Southern blot analysis, western blot analysis, and an indirect… 

Evaluation of Recombinant Herpesvirus of Turkey Laryngotracheitis (rHVT-LT) Vaccine against Genotype VI Canadian Wild-Type Infectious Laryngotracheitis Virus (ILTV) Infection

Results showed that the vaccine failed to decrease the clinical signs at 6 days post-infection, however, it was able to significantly reduce ILTV shedding through the oropharyngeal route, and overall, rHVT-LT produced a partial protection against genotype VI ILTV infection.

Protection Efficacy of a Recombinant Herpesvirus of Turkey Vaccine Against Infectious Laryngotracheitis Virus Administered In Ovo to Broilers at Three Standardized Doses

This study is the first to support that rHVT-LT vaccination did not prevent spread of challenge virus to contact birds, and lessened the challenge virus replication in the trachea.

A Cell Line Adapted Infectious Laryngotracheitis Virus Strain (BΔORFC) for in ovo and Hatchery Spray Vaccination Alone or in Combination with a Recombinant HVT-LT Vaccine

This study provides the first proof of concept that ILTV strains can be sufficiently attenuated for early vaccination in ovo or at hatch and documented the benefits of using a dual (recombinant and live attenuated) hatchery vaccination strategy for ILTV.

Virus-like particles in a new vaccination approach against infectious laryngotracheitis.

This work presents a new approach based on virus-like particles (VLPs) displaying ILTV glycoproteins B (gB) or G (gG) on their surface and reveals that the new vaccines were well tolerated in hybrid layer chicks independent of the administration method.

Attenuation and Protection Efficacy of a Recombinant Infectious Laryngotracheitis Virus (ILTV) Depleted of Open Reading Frame C (ΔORFC) when Delivered in ovo

An attenuated ILTV recombinant strain with deletion of the ORF C gene induced protection comparable to that elicited by the tissue culture origin (TCO) vaccine when administered via eyedrop.

Evaluation of vaccination against infectious laryngotracheitis (ILT) with recombinant herpesvirus of turkey (rHVT-LT) and chicken embryo origin (CEO) vaccines applied alone or in combination

This study found that priming with rHVT-LT reduced CEO virus replication and the addition of a CEO vaccination provided a more robust protection than rH VT alone, and therefore, rHvt-LT + CEO vaccination strategy constitutes an alternative approach to gain better control of the disease.

Evaluation of Protective Efficacy When Combining Turkey Herpesvirus–Vector Vaccines

The ILT product was most severely affected by the addition of other vaccines, as demonstrated by a significant increase in clinical signs, significant decrease in weight gain, and increase in quantity of challenge virus observed from tracheal swabs collected from Days 3–5 postchallenge.

Evaluation of the Protection Efficacy of a Serotype 1 Marek's Disease Virus-Vectored Bivalent Vaccine Against Infectious Laryngotracheitis and Marek's Disease

Two recombinant vaccines against MD and LT are developed by using BAC&dgr;MEQ as a vector that carries either the LT virus (LTV) gene glycoprotein B (gB; BAC &Dgr; MEQ-gB) or LTV gene glyCoprotein J (gJ; Bac&dGr;MEZ-gJ) by using serotype 1 MDV as vectors.

A double recombinant herpes virus of turkeys for the protection of chickens against Newcastle, infectious laryngotracheitis and Marek’s diseases

Results demonstrate that HVT-NDV-ILT is a safe and efficacious vaccine for simultaneous control of NDV, ILTV and Marek’s diseases.

Commercial Vaccines and Vaccination Strategies Against Infectious Laryngotracheitis: What We Have Learned and Knowledge Gaps That Remain

Recombinant viral vector ILT vaccines were first introduced in the United States in the 2000s, and now they are being used worldwide, alone or in combination with live attenuated vaccines.



Evaluation of the Efficacy of a Live Fowlpox-Vectored Infectious Laryngotracheitis/Avian Encephalomyelitis Vaccine Against ILT Viral Challenge

Overall, the results indicate that the FP-LT+AE vaccine provides adequate protection against ILT viral challenge, and proper administration is essential.

Protection of chickens from infectious laryngotracheitis with a recombinant fowlpox virus expressing glycoprotein B of infectious laryngotracheitis virus

Infectious laryngotracheitis (ILT) is an economically important disease of chickens caused by a type I gallid herpesvirus, infectious laryngotracheitis virus (ILTV). The vaccines currently available

Protection against Marek's disease by vaccination with a herpesvirus of turkeys.

HVT gives substantial protection against the development of MD yet is nonpathogenic and noncontagious, all of which are important characteristics of vaccine viruses.

Replication of recombinant herpesvirus of turkey expressing genes of infectious laryngotracheitis virus in specific pathogen free and broiler chickens following in ovo and subcutaneous vaccination

In vivo replication of rHVT-LT vaccine was slower than HVT vaccine, however, in vivo both rH VT-LT and HVT vaccines replicated at similar levels.

Studies of infectious laryngotracheitis vaccines: immunity in broilers.

There was an inverse relationship between pre-challenge VN titers of groups of birds and the percentage of birds in the groups dying from ILT virus challenge, and the drinking-water route of vaccination provided the most protection, while the spray provided the least.

Virulence of five live vaccines against avian infectious laryngotracheitis and their immunogenicity and spread after eyedrop or spray application.

Microneutralisation titres provided a useful indicator of immunity from the onset of immunity until immunity started to decline, and a vaccine virus carrier state was demonstrated by means of sentinel birds.

Studies of infectious laryngotracheitis vaccines: immunity in layers.

Ten-week-old layer chickens obtained from a commercial source were eye-drop vaccinated with chicken-embryo-origin or tissue-culture-origin vaccines for infectious laryngotracheitis, neither being significantly better than the other under these experimental conditions.

Mild Infectious Laryngotracheitis in Broilers in the Southeast

Restriction fragment length polymorphism analysis of ILT PCR products indicated that ILT virus associated with mild respiratory disease in the Southeast is related to the chicken embryo origin vaccine type strains.

Characterization of Infectious Laryngotracheitis Virus (ILTV) Isolates from Commercial Poultry by Polymerase Chain Reaction and Restriction Fragment Length Polymorphism (PCR-RFLP)

In general, groups V and VI were the most prevalent viruses, found in 52% and 33% of the samples tested respectively, and both types of viruses were detected in vaccinated and nonvaccinated flocks.

Comparison of Diagnostics Techniques in an Outbreak of Infectious Laryngotracheitis from Meat Chickens

Polymerase chain reaction was the most sensitive test and detected the viral DNA even in cases where histology and FA were negative, and FA test has the advantage over histology of being diagnostically specific for ILT virus.